New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:40 EDTTKPYYMillennium and Takeda report data from Phase I trial of ADCETRIS
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced results from two arms of a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma, MTCL, patients, including patients with systemic anaplastic large cell lymphoma, sALCL. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate, ADC, directed to CD30. ADCETRIS is not approved for use in the front-line treatment of MTCL.
News For TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 12, 2015
19:33 EDTTKPYYOrexigen provides update on Contrave collaboration with Takeda
Subscribe for More Information
19:32 EDTTKPYYOrexigen provides statement on termination of Light Study
Subscribe for More Information
17:52 EDTTKPYYTakeda requesting Orexigen to pay cost of second heart trial, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use